Ubs Group Ag Bio Line Rx Ltd. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 984 shares of BLRX stock, worth $216. This represents 0.0% of its overall portfolio holdings.

Number of Shares

984

Previous 1,480 33.51%

Holding current value

$216

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.53 - $0.87 $262 - $431	-496 Reduced 33.51%	984 $0
Q2 2024 Aug 13, 2024	SELL	$0.56 - $0.86 $6,209 - $9,536	-11,089 Reduced 88.22%	1,480 $0
Q1 2024 May 13, 2024	BUY	$1.03 - $1.56 $12,637 - $19,139	12,269 Added 4089.67%	12,569 $14,000
Q4 2023 Feb 09, 2024	SELL	$1.31 - $1.86 $11,765 - $16,704	-8,981 Reduced 96.77%	300 $0
Q3 2023 Nov 09, 2023	SELL	$1.23 - $2.45 $1,544 - $3,077	-1,256 Reduced 11.92%	9,281 $16,000
Q2 2023 Aug 11, 2023	BUY	$0.96 - $1.78 $10,115 - $18,755	10,537 New	10,537 $16,000
Q4 2022 Feb 08, 2023	SELL	$0.57 - $0.95 $5,111 - $8,518	-8,967 Reduced 70.09%	3,826 $2,000
Q3 2022 Nov 10, 2022	BUY	$0.88 - $1.91 $11,257 - $24,434	12,793 New	12,793 $12,000
Q3 2021 Nov 15, 2021	SELL	$2.65 - $3.35 $16,684 - $21,091	-6,296 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$2.63 - $4.88 $2,548 - $4,728	-969 Reduced 13.34%	6,296 $18,000
Q1 2021 May 12, 2021	BUY	$2.38 - $4.0 $2,882 - $4,844	1,211 Added 20.0%	7,265 $20,000
Q4 2020 Feb 11, 2021	BUY	$1.47 - $3.62 $2,763 - $6,805	1,880 Added 45.04%	6,054 $15,000
Q3 2020 Nov 12, 2020	BUY	$1.56 - $2.37 $6,511 - $9,892	4,174 New	4,174 $7,000
Q4 2019 Feb 14, 2020	SELL	$1.97 - $2.97 $2,125 - $3,204	-1,079 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.56 - $5.25 $2,762 - $5,664	1,079 New	1,079 $3,000

Others Institutions Holding BLRX

# of Institutions

Shares Held

3.35M

Call Options Held

46.5K

Put Options Held

6.3K

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $13.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account